Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on November 21, 2022, covering an event that occurred on November 16, 2022. The company is a Nevada corporation with its principal executive offices in Boca Raton, Florida, and its common stock trades on the NASDAQ under the symbol "INMB". The registrant is classified as an emerging growth company.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on a corporate governance event regarding insider trading plans.
Material Changes
The material event reported is the establishment of a Rule 10b5-1 trading plan by CTI Holdings, Inc. ("CTI"). Key details include:
- Plan Scope: The plan covers the trading of 60,000 shares of Inmune Bio common stock.
- Ownership Context: These shares represented approximately 0.33% of the company's issued and outstanding common stock as of November 4, 2022.
- Control: Timothy J. Schroeder, a member of the Company's board of directors, is the majority shareholder of CTI and holds voting and investment control over these shares.
- Duration: The CTI Plan is scheduled to terminate on November 4, 2024.
Guidance, Outlook, and Risks
The filing provides no financial guidance, outlook, or management commentary regarding the company's business operations. The primary purpose of the Rule 10b5-1 plan is to allow insiders to execute pre-determined stock transactions for asset diversification and tax planning without possessing material non-public information. The company states it has no obligation to report modifications or terminations of this plan except as required by applicable securities laws.
Investor Verification Checklist
- Verify the current ownership percentage of CTI Holdings, Inc. and Timothy J. Schroeder relative to the total outstanding shares.
- Monitor future Form 4 filings to track actual transactions executed under the CTI Plan.
- Confirm the termination date of the plan (November 4, 2024) against any potential early termination notices.
- Review the company's most recent 10-K or 10-Q for actual financial performance metrics, as this 8-K contains none.